Prima Biomed Backpedals After Inconclusive PFS
Shares of Australia’s Prima Biomed Ltd. were jolted Wednesday after top-line data from the company’s Phase II study of cancer vaccine candidate Cvac showed no observed difference in estimated median progression-free survival (PFS) compared to control in epithelial ovarian cancer patients in first or second remission. On the Nasdaq Global Market – the first of the company’s public markets to react to the news – shares (NASDAQ:PBMD) fell 74 cents, or 31.3 percent, to close at $1.61.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter